Golden S.H., Robinson K.A., Saldanha I. et al. Prevalence and incidence endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 2009;94(6):1853–78.
DOI: 10.1210/jc.2008-2291

Grundy S.M., Cleeman J.I., Daniels S.R. et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 2005;112(17):2735–52.
DOI: 10.1161/ CIRCULATIONAHA.105.169404

Тюзиков И.А. Метаболический синдром и мужское бесплодие (обзор литературы). Андрология и генитальная хирургия 2013;14(2):5–10..
DOI: 10.17650/2070-9781-2013-2-7-10.

Grossman H., Fabre B., Lopez M. et al. Complex relationship between sex hormones, insulin resistance and leptin in men with and without prostatic disease. Aging Male 2015;19(1):40–5.
DOI: 10.3109/13685538.2015.1100600

Andriole G., Bruchovsky N., Chung L.W. et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004;172(4 Pt 1): 1399–403

Gorbachinsky I., Akpinar H., Assimos D.G. Metabolic syndrome and urologic diseases. Rev Urol 2010;12(4):e157–80

Churilla J.R., Fitzhugh E.C., Thompson D.L. The metabolic syndrome: how definition impacts the prevalence and risk in U.S. adults: 1999–2004 NHANES. Metab Syndr Relat Disord 2007;5(4):331–42.
DOI: 10.1089/ met.2007.0010

Тюзиков И.А., Фомин А.М., Калинченко С.Ю., Мартов А.Г. Системный патогенез заболеваний предстательной железы (литературный обзор). Андрология и генитальная хирургия 2012;(2):4–12..

Кирпатовский В.И., Мкртчян К.Г., Фролова Е.В., Казаченко А.В. Роль гормональных факторов и нарушения кровоснабжения предстательной железы в патогенезе ДГПЖ. Экспериментальная и клиническая урология. 2013;(2):38–45..

Vignozzi L., Morelli A., Sarchielli E. et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol 2012;212(1):71–84.
DOI: 10.1530/JOE-11-0289

Kim M.K., Zhao C., Kim S.D. et al. Relationship of sex hormones and nocturia in lower urinary tract symptoms induced by benign prostatic hyperplasia. Aging Male 2012;15(2):90–5.
DOI: 10.3109/13685538.2012.659715

Di Bello J.R., Ioannou C., Rees J. et al. Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: a large cross-sectional, UK epidemiological study. BJU Int 2016;117(5):801–8.
DOI: 10.1111/bju.13334

Ryl A., Rotter I., Miazgowski T. et al. Metabolic syndrome and benign prostatic hyperplasia: association or coincidence? Diabetol Metab Syndr 2015;7:94.
DOI: 10.1186/s13098-015-0089-1

Pan J.H., Jiang C., Luo R., Zhou X. Association of metabolic syndrome and benign prostatic hyperplasia in Chinese patients of different age decades. Urol Int 2014;93(1):10–6.
DOI: 10.1159/000354026

Zhao S., Chen C., Chen Z. et al. Relationship between metabolic syndrome and predictors for clinical benign prostatic hyperplasia progression and International Prostate Symptoms Score in patients with moderate to severe lower urinary tract symptoms. Urol J 2016;13(3):2717–26

Loeb S., Kettermann A., Carter H.B. et al. Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging. J Urol 2009;182(4):1458–62.
DOI: 10.1016/j.juro.2009.06.047

Wang J.E., Fu Y.Y., Kang D.Y. The association between metabolic syndrome and characteristics of benign prostatic hyperplasia. A systematic review and meta-analysis. Medicine (Baltimore) 2016;95(19):e3243.
DOI: 10.1097/ MD.0000000000003243

Zhang X., Zong X., Liu Y. et al. Impact of metabolic syndrome on benign prostatic hyperplasia in elderly Chinese men. Urol Int 2014;93(2):214–9.
DOI: 10.1159/000357760

Cao B., Sun H.B., Su J.H. et al. Correlation between metabolic syndrome and clinical progression in patients with benign prostatic hyperplasia. Zhonghua Yi Xue Za Zhi 2010;90(40):2823–5

De Nunzio C., Cindolo L., Gacci M. et al. Metabolic syndrome and lower urinary tract symptoms in patients with benign prostatic enlargement: a possible link to storage symptoms. Urology 2014;84(5):1181–7.
DOI: 10.1016/j.urology.2014.07.018

Gacci M., Corona G., Vignozzi L. et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and metaanalisys. BJU Int 2015;115(1):24–31.
DOI: 10.1111/bju.12728

Kwon H., Kang H.C., Lee J.H. Relationship between predictors of the risk of clinical progression of benign prostatic hyperplasia and metabolic syndrome in men with moderate to severe lower urinary tract symptoms. Urology 2013;81(6):1325–9.
DOI: 10.1016/j. urology.2013.01.042

Dahle S.E., Chokkalingam A.P., Gao Y.T. et al. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002;168(2):599–604

Hammarsten J., Högstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001;39(2):151–8

Martin S.A., Haren M.T., Marshall V.R. et al. Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. World J Urol 2011;29(2):179–84.
DOI: 10.1007/s00345-010-0605-8

Telli O., Demirbas A., Kabar M. et al. Does metabolic syndrome or its components correlate with lower urinary tract symptoms in benign prostatic hyperplasia patients? Nephrourol Mon 2015;7(3):e27253.
DOI: 10.5812/numonthly.7(3)2015.27253

Gao Y., Wang M.J., Zhang H.Y. et al. Are metabolic syndrome and its components associated with lower urinary tract symptoms? Results from Chinese male population survey. Urology 2012;79(1):194–201.
DOI: 10.1016/j.urology.2011.07.1399

Yang T.K., Hsieh J.T., Chen S.C. et al. Metabolic syndrome associated with reduced lower urinary tract symptoms in middle-aged men receiving health checkup. Urology 2012;80(5):1093–7.
DOI: 10.1016/j.urology.2012.08.002

Byun H.K., Sung Y.H., Kim W. et al. Relationship between prostate-specific antigen, prostate volume and components of metabolic syndrome in healthy Korean men. Korean J Urol 2012;53(11):774–8.
DOI: 10.4111/kju.2012.53.11.774

Park Y.W., Kim S.H., Kwon H. et al. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome. Urology 2013;82(3):674–9.
DOI: 10.1016/j.urology.2013.03.047

Pashootan P., Ploussard G., Cocaul A. et al. Association between metabolic syndrome and severity of lower urinary tract symptoms (LUTS): an observational study in a 4666 European men cohort. BJU Int 2015;116(1):124–30.
DOI: 10.1111/bju.12931

Yim S.J., Cho Y.S., Joo K.J. Relationship between metabolic syndrome and prostate volume in Korean men under 50 years of age. Korean J Urol 2011;52(6):390–5.
DOI: 10.4111/kju.2011.52.6.390

Russo G.I., Castelli T., Urzi D. et al. Emerging links between non-neurogenic lower urinary tract symptoms secondary to benign prostatic obstruction, metabolic syndrome and its components: a systematic review. Int J Urol 2015;22(11):982–90.
DOI: 10.1111/iju.12877

Тюзиков И.А., Греков Е.А., Калинченко С.Ю. Варианты клинического течения и морфометрических параметров доброкачественной гиперплазии предстательной железы у мужчин с метаболическим синдромом и андрогенным дефицитом. Урология 2015;(3):66–9..

Azzouni F., Godoy A., Li Y., Mohler J. The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv Urol 2012;2012:530121.
DOI: 10.1155/2012/530121

Kobayashi H., Gotanda K., Shibata Y. et al. Suppressive effects of the antiandrogen agent, chlormadinone acetate and the 5alpha-reductase inhibitor, dutasteride on prostate weight and intraprostatic androgen levels in rats. Arzneimittelforschung 2011;61(9):515–20.
DOI: 10.1055/s-0031-1296237

Kumar R., Verma V., Sarswat A. et al. Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms – action of two new agents. Invest New Drugs 2012;30(2):582–93.
DOI: 10.1007/s10637-010-9620-2

Кирпатовский В.И., Чочуев О.С., Голованов С.А. и др. Экспериментально вызванный метаболический синдром у крыс: патогенез развития ДГПЖ и дисфункции мочеиспускания. Экспериментальная и клиническая урология 2016;(4):4–12..

Ленинджер А. Биохимия. М.: Мир, 2004. С. 422..

Mitterberger M., Pallwein L., Gradl J. et al. Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder. BJU Int 2007;99(4):831–5.
DOI: 10.1111/j.1464-410X.2006.06735.x

Okutsu H., Matsumoto S., Hanai T. et al. Effects of tamsulosin on bladder blood flow and bladder function in rats with bladder outlet obstruction. Urology 2010;75(1):235–40.
DOI: 10.1016/j. urology.2009.05.045

Baykam M.N., Aktas B.K., Bulut S. et al. Association between prostatic resistive index and cardiovascular risk factors in patients with benign prostatic hyperplasia. Kaohsiung J Med Sci 2015;31(4):194–8.
DOI: 10.1016/j. kjms.2014.12/008

Navarro-Dorado J., Orensanz L.M., Recio P. et al. Mechanisms involved in testosterone-induced vasodilatation in pig prostatic small arteries. Life Sci 2008;83(15–16):569–73.
DOI: 10.1016/j. lfs.2008.08.009

Polisca A., Orlandi R., Troisi A. et al. Clinical efficacy of the GnRH agonist (deslorelin) in dogs affected by benign prostatic hyperplasia and evaluation of prostatic blood flow be Doppler ultrasound. Reprod Domest Anim 2013;48(4):673–80.
DOI: 10.1111/rda.12143

Жуков О.Б., Зубарев А.Р., Кульченко Л.Г. Влияние андрогенозаместительной терапии на гемодинамические параметры интраорганного кровотока органов-мишеней тестостерона. Андрология и генитальная хирургия 2008;(1):31–5..

Цыганкова О.В., Николаев К.Ю., Федорова Е.Л., Бондарева З.Г. Обмен половых гормонов в организме мужчины через призму кардиоваскулярного риска. Атеросклероз и дислипидемия 2014;(1):17–24..

Nicholson T.M., Ricke W.A. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 2011;82(4–5):184–99.
DOI: 10.1016/j.diff.2011.04.006

Daehlin L., Damber J.E., Selstam G., Bergman B. Testosterone-induced decrement of prostatic vascular resistance in rats is reversed by estrogens. Prostate 1985;6(4):351–9

Wu J.H., Jiang X.R., Liu G.M. et al. Oral exposure to low-dose bisphenol A aggravates testosterone-induced benign hyperplasia prostate in rats. Toxicol Ind Health 2011;27(9):810–9.
DOI: 10.1177/0748233711399310

Comeglio P., Morelli A., Cellai I. et al. Opposite effects of tamoxifen on metabolic syndrome-induced bladder and prostate alterations: a role for GPR30/ GPER? Prostate 2014;74(1):10–28.
DOI: 10.1002/pros.22723

Morelli A., Comeglio P., Filippi S. et al. Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndromeassociated prostate alterations: An experimental study in the rabbit. Prostate 2013;73(4):428–41.
DOI: 10.1002/pros.22584

Есилевский Ю.М. Действие ингибиторов фосфодиэстеразы 5-го типа на гемодинамику пузырно-уретрального сегмента. В сб.: Материалы XIII Конгресса Российского общества урологов. М., 2013. С. 319–20..

Giuliano F., Ückert S., Maggi M. et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol 2013;63(3):506–16.
DOI: 10.1016/j.eururo.2012.09.006

Vikram A., Jena G. Role of insulin and testosterone in prostatic growth: who is doing what? Med Hypotheses 2011;76(4):474–8.
DOI: 10.1016/j. mehy.2010.11.024

Wang Z., Olumi A.F. Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia. Differentiation 2011;82(4–5):261–71.
DOI: 10.1016/j. diff.2011.04.004

Калинченко С.Ю., Тюзиков И.А., Ворслов Л.О., Тишова Ю.А. Ожирение, инсулинорезистентность и репродуктивное здоровье мужчины: патогенетические взаимодействия и современная патогенетическая фармакотерапия. Эффективная фармакотерапия 2015;(27):66–79..

Ribeiro D.L., Pinto M.E., Maeda S.Y. et al. High fat-induced obesity associated with insulin-resistance increases FGF-2 content and causes stromal hyperplasia in rat ventral prostate. Cell Tissue Res 2012;349(2):577–88.
DOI: 10.1007/s00441-012-1420-x

Калинченко С.Ю., Тюзиков И.А., Греков Е.А. и др. Андрогены и симптомы нарушения функции нижних мочевых путей: исключительно мужская гендерность или нерешенная проблема обоих полов? Экспериментальная и клиническая урология 2013;(4):40–8..

Тюзиков И.А., Братчиков О.И., Михайлов Д.В. и др. Роль возрастного андрогенного дефицита в патогенезе аденомы предстательной железы. Тихоокеанский медицинский журнал 2016;(1):14–8..

Vignozzi L., Cellai I., Santi R. et al. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol 2012;214(1):31–43.
DOI: 10.1530/JOE-12-0142

Vignozzi L., Filippi S., Comeglio P. et al. Tadalafil effect on metabolic syndromeassociated bladder alterations: an experimental study in rabbit model. J Sex Med 2014;11(5):1159–72.
DOI: 10.1111/jsm.12478

Gacci M., Vignozzi L., Sebastianelli A. et al. Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis 2013;16(1):101–6.
DOI: 10.1038/ pcan.2012.44

Morgia G., Cimino S., Favilla V. et al. Effects of Serenoa repens, selenium and lycopene (Profluss®) on chronic inflammation association with benign prostatic hyperplasia: results of “FLOG” (Flogosis and Profluss in Prostatic and Genital Diseases), a multicenter Italian study. Int Braz J Urol 2013;39(2):214–21.
DOI: 10.1590/S1677-5538. IBJU.2013.02.10

Калинченко С.Ю., Ворслов Л.О., Тюзиков И.А., Тишова Ю.А. Окислительный стресс как причина системного старения. Роль препаратов α-липоевой кислоты (Эспа-Липон) в лечении и профилактике возраст-ассоциированных заболеваний. Фарматека 2014;(6):43–54..

Vanella L., Russo G.I., Cimino S. et al. Correlation between lipid profile and heme oxygenase system in patients with benign prostatic hyperplasia. Urology 2014;83(6):1444.e7–13.
DOI: 10.1016/j.urology.2014.03.007

He Q., Wang Z., Liu G. et al. Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational risks. Prostate Cancer Prostatic Dis 2016;19(1):7–13.
DOI: 10.1038/pcan.2015.43

Ozer K., Horsanali M.O., Gorgel S.N. et al. Association between benign prostatic hyperplasia and neutrophil-lymphocyte ratio, an indicator of inflammation and metabolic syndrome. Urol Int 2017;98(4):466–71.
DOI: 10.1159/000448289

Cantiello F., Cicione A., Salonia A. et al. Periurethral fibrosis secondary to prostatic inflammation causing lower urinary tract symptoms: a prospective cohort study. Urology 2013;81(5):1018–23.
DOI: 10.1016/j.urology.2013.01.053

Gharaee-Kermani M., RodriguezNieves J.A., Mehra R. et al. Obesity-induced diabetes and lower urinary tract fibrosis promote urinary voiding dysfunction in a mouse model. Prostate 2013;73(10):1123–33.
DOI: 10.1002/pros.22662

Sener N.C., Zengin K., Ozturk U. et al. The impact of metabolic syndrome on the outcomes of transurethral resection of the prostate. J Endourol 2015;29(3):340–3.
DOI: 10.1089/end.2014.0562

Akin Y., Gulmez H., Atez E. et al. Preliminary assessment of neck circumference in benign prostatic hyperplasia in patients with metabolic syndrome. Int Braz J Urol 2017;43(1):95–103.
DOI: 10.1590/S1677-5538. IBJU.2016.0139

Cyrus A., Kabir A., Goodarzi D. et al. Impact of metabolic syndrome on response to medical treatment of benign prostatic hyperplasia. Korean J Urol 2014;55(12):814–20.
DOI: 10.4111/ kju.2014.55.12.814